273 related articles for article (PubMed ID: 12766582)
1. CD10 imunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis.
Srodon M; Klein WM; Kurman RJ
Am J Surg Pathol; 2003 Jun; 27(6):786-9. PubMed ID: 12766582
[TBL] [Abstract][Full Text] [Related]
2. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis.
Nascimento AF; Hirsch MS; Cviko A; Quade BJ; Nucci MR
Mod Pathol; 2003 Jan; 16(1):22-7. PubMed ID: 12527709
[TBL] [Abstract][Full Text] [Related]
3. CD10 immunostaining distinguishes atypical polypoid adenomyofibroma (atypical polypoid adenomyoma) from endometrial carcinoma invading the myometrium.
Ohishi Y; Kaku T; Kobayashi H; Aishima S; Umekita Y; Wake N; Tsuneyoshi M
Hum Pathol; 2008 Oct; 39(10):1446-53. PubMed ID: 18619643
[TBL] [Abstract][Full Text] [Related]
4. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion.
Ismiil N; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Ackerman I; Thomas G; Covens A; Khalifa MA
Ann Diagn Pathol; 2007 Aug; 11(4):252-7. PubMed ID: 17630108
[TBL] [Abstract][Full Text] [Related]
5. Adenomyosis is associated with myometrial invasion by FIGO 1 endometrial adenocarcinoma.
Ismiil ND; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Thomas G; Ackerman I; Covens A; Khalifa MA
Int J Gynecol Pathol; 2007 Jul; 26(3):278-83. PubMed ID: 17581412
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical characteristics of atypical polypoid adenomyoma with special reference to h-caldesmon.
Horita A; Kurata A; Maeda D; Fukayama M; Sakamoto A
Int J Gynecol Pathol; 2011 Jan; 30(1):64-70. PubMed ID: 21131830
[TBL] [Abstract][Full Text] [Related]
7. IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma.
Busca A; Djordjevic B; Giassi A; Parra-Herran C
Am J Clin Pathol; 2016 Apr; 145(4):486-96. PubMed ID: 27124937
[TBL] [Abstract][Full Text] [Related]
8. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
[TBL] [Abstract][Full Text] [Related]
9. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody.
Sumathi VP; Al-Hussaini M; Connolly LE; Fullerton L; McCluggage WG
Int J Gynecol Pathol; 2004 Jul; 23(3):241-7. PubMed ID: 15213600
[TBL] [Abstract][Full Text] [Related]
10. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
11. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis.
Mittal KR; Barwick KW
Gynecol Oncol; 1993 May; 49(2):197-201. PubMed ID: 8504988
[TBL] [Abstract][Full Text] [Related]
12. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.
McCluggage WG; Sumathi VP; Maxwell P
Histopathology; 2001 Sep; 39(3):273-8. PubMed ID: 11532038
[TBL] [Abstract][Full Text] [Related]
13. CD10 is a marker for normal and neoplastic endometrial stromal cells.
Toki T; Shimizu M; Takagi Y; Ashida T; Konishi I
Int J Gynecol Pathol; 2002 Jan; 21(1):41-7. PubMed ID: 11781522
[TBL] [Abstract][Full Text] [Related]
14. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases.
Chu PG; Arber DA; Weiss LM; Chang KL
Mod Pathol; 2001 May; 14(5):465-71. PubMed ID: 11353058
[TBL] [Abstract][Full Text] [Related]
15. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion.
Quick CM; May T; Horowitz NS; Nucci MR
Int J Gynecol Pathol; 2012 Jul; 31(4):337-43. PubMed ID: 22653347
[TBL] [Abstract][Full Text] [Related]
16. [Highly cellular leiomyoma of uterus: a comparative morphologic and immunohistochemical study of endometrial stromal tumors].
Liao X; Wang Y; Yue C; Liu Y; Wang H; Dai L; Hui Y
Zhonghua Bing Li Xue Za Zhi; 2002 Oct; 31(5):396-400. PubMed ID: 12485478
[TBL] [Abstract][Full Text] [Related]
17. Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases.
Jacques SM; Lawrence WD
Gynecol Oncol; 1990 Jun; 37(3):401-7. PubMed ID: 2351325
[TBL] [Abstract][Full Text] [Related]
18. Stromal p16 Expression Helps Distinguish Atypical Polypoid Adenomyoma From Myoinvasive Endometrioid Carcinoma of the Uterus.
Kihara A; Amano Y; Yoshimoto T; Matsubara D; Fukushima N; Fujiwara H; Niki T
Am J Surg Pathol; 2019 Nov; 43(11):1526-1535. PubMed ID: 31600177
[TBL] [Abstract][Full Text] [Related]
19. [Myxoid mesenchymal tumors of uterus: endometrial stromal and smooth muscle tumors, myxoid variant].
Chesnais AL; Watkin E; Beurton D; Devouassoux-Shisheboran M
Ann Pathol; 2011 Jun; 31(3):152-8. PubMed ID: 21736994
[TBL] [Abstract][Full Text] [Related]
20. Use of myocardin in the classification of mesenchymal tumors of the uterus.
Liang J; Wu L; Xiao H; Li N; Wang H; Cheng C; Bai R; Zhao Y; Zheng H
Int J Gynecol Pathol; 2010 Jan; 29(1):55-62. PubMed ID: 19952936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
